Virios Therapeutics Q2 2024 GAAP EPS $(0.05), Inline
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics (NASDAQ:VIRI) reported Q2 2024 GAAP EPS of $(0.05), which met analyst expectations and showed a 37.5% improvement from the $(0.08) loss per share in the same period last year.
August 08, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Virios Therapeutics reported Q2 2024 GAAP EPS of $(0.05), meeting analyst expectations and improving by 37.5% from the previous year's $(0.08) per share loss.
Meeting analyst expectations and showing a significant improvement in EPS from the previous year is a positive indicator for the company's financial health, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100